3 Stocks to Buy From the World's Greatest Growth Portfolio

Just before 2012 started, a group of family and friends asked me to give them advice on building out the ideal growth portfolio. I split my picks into three groups based on risk: core investments, tier one investments, and riskier tier two investments.

Below, I share with you how the hypothetical portfolio is doing, why it's doing so well -- though not nearly as well as just one month ago -- and I'll offer up my three best buys from the group right now.

Read all the way to the end, and I'll throw in access to a special free report about the social media play that isn't getting enough attention right now.

Core

Company

Allocation

Jan. 1 Balance

March 3 Balance

Change

Intuitive Surgical 11.5%  $115.00  $124.89 8.6%
Google 11.5%  $115.00  $101.78 (11.5%)
Amazon.com 11.5%  $115.00  $138.23 20.2%
Whole Foods 11.5%  $115.00  $141.57 23.1%

Tier One

lululemon athletica 7.5%  $75.25  $111.75 48.5%
Apple (Nasdaq: AAPL  ) 7.5%  $75.25  $104.22 38.5%
Westport Innovations (Nasdaq: WPRT  ) 7.5%  $75.25  $52.75 (29.9%)
IPG Photonics (Nasdaq: IPGP  ) 7.5%  $75.25  $88.12 17.1%

Tier Two

Baidu (Nasdaq: BIDU  ) 5%  $50.00  $48.70 (2.6%)
Zipcar 5%  $50.00  $36.00 (28%)
Stratasys 5%  $50.00  $72.50 45%
MAKO Surgical (Nasdaq: MAKO  ) 5%  $50.00  $42.90 (14.2%)
Solazyme 5%  $50.00  $44.05 (11.9%)
         
Total 100%  $1,000.00  $1,107.45 10.7%

Source: Fool.com; includes reinvested dividends, as of market close, June 1, 2012.

When I sat down to write this article last month, my growth portfolio had returned an astounding 28% year to date. Those returns have gotten cut by more than half since then -- yet we are still beating the S&P 500 by 8.5 percentage points.

Several factors converged to beat down the portfolio in May. Most generally, there was a plethora of bad macroeconomic news that hit the presses -- from worries about European sovereign debt to slowed U.S. growth. When such news hits, growth companies in particular are hard hit, and the past month was no exception.

Take the case of Westport Innovations, a company that designs natural gas engines for trucks. In just the course of a week, Westport notched double-digit percentage gains -- and followed that up with equally bad losses. When the market is this unsure about a company, I take solace in the fact that, as a long-term investor, most of these gyrations will smooth themselves out over the decades.

By far my biggest loser in May, though, was MAKO Surgical. The company reported fewer procedures and RIO Surgical System sales than were expected, and the market roundly punished shareholders. Shares are down almost 50% since May 1.

Three best buys
Even though I believe the two aforementioned companies have bright futures, they didn't make the cut for my best buys for this month. The first company that did make the list is Apple. I like what famed investor David Einhorn recently pointed out: Apple is a severely misunderstood company -- its real strength is in software, not hardware. People like it when their electronics can communicate with each other -- as is possible with iOS.

"Once the user has a second device, [Apple] has captured the customer. At that point, a future competitor has to make a product that isn't just a little better, but a lot better to get people to switch," Einhorn stated.

Next on the list is Baidu -- otherwise known as the "Google of China." The company grew earnings by 76% and revenue by 75% last quarter. Despite this, Baidu trades at just 34 times earnings, and has a PEG ratio as low as Apple's -- at 0.59. Bears are right to be worried about slower growth in China, but they are missing the bigger point: Not even half of China's growing population have become regular Internet users yet. As more of China comes online, advertisers will pay Baidu top dollar for the company's advertising exposure.

Finally, we have IPG Photonics. I actually called the company out as a potential investment this month for my Roth IRA. IPG's lasers are on the cusp of overtaking conventional lasers in a number of different markets. The company offers a better, more reliable product for less than competitors charge.

Shares are down 28% over the past month, mostly on macroeconomic concerns. The company's lasers are primarily used for industrial welding, and a global economic slowdown would shrink demand.  Despite these concerns, the company is a solid long-term buy in my book.

Forget Facebook
One of the most important traits of becoming a better growth investor is to know when to ignore the noise about the "next hot stock." No company has been getting more unwarranted attention right now than Facebook.

We've put together a special free report to detail what most growth investors are overlooking: "Forget Facebook -- Here's the High-Tech IPO You Should Be Buying." Inside, you'll get the name of a social media play that could be a big winner. Find out what it is by getting a copy of the report today, absolutely free!

Fool contributor Brian Stoffel owns shares of all the companies mentioned except Facebook. You can follow him on Twitter, where he goes by TMFStoffel.

The Motley Fool owns shares of Facebook, Google, Amazon.com, lululemon athletica, Whole Foods Market, Solazyme, Baidu, MAKO Surgical, IPG Photonics, Apple, Intuitive Surgical, Westport Innovations, and Zipcar. Motley Fool newsletter services have recommended buying shares of Zipcar, lululemon athletica, IPG Photonics, Google, Stratasys, Amazon.com, MAKO Surgical, Westport Innovations, Apple, Intuitive Surgical, Baidu, and Whole Foods, as well as creating a bull call spread position in Apple. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (1) | Recommend This Article (14)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 04, 2012, at 2:05 PM, MrSinnister wrote:

    Why not do an in-depth research report on both why Discovery Labs isn't moving and why now is the perfect time to both invest in Biotechs and DSCO? They have been major M&A targets the past Spring, and I don't see that stopping in the near future.

    Received FDA approval for 1 of its drugs, SURFAXIN, and its nebulizer Affectair on March 5th of this year. PPS Spiked at 5.39 until a week later, a secondary offering of 16 million shares @2.80 was submitted, killing the momentum from the FDA approval and leaving it in the doldrums where it sits today, lagging behind companies with only ONE drug and deeply in the red like Seattle Genetics SGEN, currently trading at over 19. DSCO is slated to have it's distribution pipeline for its infant RDS (Respiratory Distress Syndrome) drug out by the end of the year, with EU approval next year. Trading at currently 2.52, this stock could be the steal of the year, and can actually beat Bank of America (before the crises) as comeback stock or Stock of the Year. The volume is currently dismal as longs have rooted into their positions and currently not selling. Check it out and do your own due diligence.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1902119, ~/Articles/ArticleHandler.aspx, 10/31/2014 2:25:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement